0000000000659788

AUTHOR

Florian Stehling

showing 5 related works from this author

Coil embolisation for massive haemoptysis in cystic fibrosis.

2021

IntroductionMassive haemoptysis is a life-threatening event in advanced cystic fibrosis (CF) lung disease with bronchial artery embolisation (BAE) as standard of care treatment. The aim of our study was to scrutinise short-term and long-term outcomes of patients with CF and haemoptysis after BAE using coils.MethodsWe carried out a retrospective cohort study of 34 adult patients treated for massive haemoptysis with super selective bronchial artery coil embolisation (ssBACE) between January 2008 and February 2015. Embolisation protocol was restricted to the culprit vessel(s) and three lobes maximum. Demographic data, functional end-expiratory volume in 1 s in % predicted (FEV1% pred.) and bod…

Pulmonary and Respiratory MedicineAdultmassive haemoptysismedicine.medical_specialtyHemoptysisCystic FibrosisMedizinBronchial ArteriesCulpritCystic fibrosisDiseases of the respiratory systemmedicine.arterymedicineHumansIn patient22181506Coil embolizationRetrospective StudiesRC705-779business.industryRRetrospective cohort studymedicine.diseaseEmbolization TherapeuticSurgeryMedicineSputummedicine.symptomBronchial arterybusinessBody mass indexBMJ open respiratory research
researchProduct

Diagnostik und Therapie des Morbus Pompe im Kindesalter

2020

Pompe disease is a rare metabolic myopathy caused by deficiency of lysosomal α-glucosidase. Reduced enzyme activity results in abnormal intra- and extralysosomal glycogen deposition as well as impaired cellular function and autophagy. Age at manifestation and severity of disease depend on residual enzyme activity. Enzyme replacement therapy (ERT) is available since 2006. In infantile onset Pompe disease, the most severe form, markedly prolonged survival has resulted in a new phenotype with symptoms and problems not encountered previously. In addition, it became apparent that antibody formation against the recombinant human enzyme may adversely affect the response to ERT. This review summari…

Pediatricsmedicine.medical_specialtybiologybusiness.industryAutophagy030232 urology & nephrologyMedizinGlycogen deposition610 Medicine & healthDiseaseMetabolic myopathyEnzyme replacement therapymedicine.diseaseEnzyme assay03 medical and health sciences0302 clinical medicine10036 Medical Clinic030225 pediatricsPediatrics Perinatology and Child HealthGlycogen storage disease type IImedicinebiology.proteinbusinessAntibody formation
researchProduct

Pädiatrisch-pneumologische Aspekte der Schlafmedizin

2013

Der plotzliche Sauglingstod oder Sudden Infant Death (SID) wird definiert als der plotzliche Tod eines Sauglings, der aufgrund der Anamnese unerwartet ist und bei dem eine grundliche postmortale Untersuchung – einschlieslich einer Beurteilung der Auffindesituation – keine adaquate Todesursache zu zeigen vermag.

researchProduct

Hypersensitivity pneumonitis : Lessons from a randomized controlled trial in children

2021

Introduction Hypersensitivity pneumonitis (HP) in children is a severe interstitial lung disease and potentially, a chronic condition, if not treated appropriately. No evidence-based guidelines are available; in particular, the role of systemic glucocorticoid therapy is unclear. Methods The aim of this randomized, double-blind, placebo-controlled, parallel-group, multi-center, phase II trial in pediatric HP was to assess the outcome of HP in children after 6 months of treatment and to compare 3 months of treatment with oral prednisolone or placebo. Results After 1.5 years and the inclusion of only four children, we terminated the study prematurely. Two of the children randomized to predniso…

Pulmonary and Respiratory MedicineAdultChronic conditionPediatricsmedicine.medical_specialtyPrednisoloneMedizinPlacebolaw.inventionFEV1/FVC ratioRandomized controlled trialDouble-Blind MethodlawMedicineHumansChildGlucocorticoidsbusiness.industryInterstitial lung diseasemedicine.diseaseClinical trialPediatrics Perinatology and Child HealthPrednisolonebusinessLung Diseases InterstitialHypersensitivity pneumonitismedicine.drugAlveolitis Extrinsic Allergic
researchProduct

Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial.

2010

Summary Background Duchenne muscular dystrophy is a rare X-linked progressive disease characterised by loss of ambulation at about age 10 years, with death in early adulthood due to respiratory and cardiac insufficiency. Steroids are effective at slowing the progression of muscle weakness; however, their use is limited by side-effects, prompting the search for alternatives. We assessed the effect of ciclosporin A as monotherapy and in combination with intermittent prednisone for the treatment of ambulant patients with this disorder. Methods Our study was a parallel-group, placebo-controlled, double-blind, multicentre trial at trial sites of the German muscular dystrophy network, MD-NET, ove…

Malemedicine.medical_specialtyDuchenne muscular dystrophyMedizinPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawPrednisoneInternal medicinemedicineHumansMuscular dystrophyChild030304 developmental biology0303 health sciencesbusiness.industryMuscle weaknessmedicine.diseaseCiclosporin3. Good healthSurgeryClinical trialMuscular Dystrophy DuchenneReview Literature as TopicTreatment OutcomeCyclosporineNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgerymedicine.drugThe Lancet. Neurology
researchProduct